Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies.

Autor: Pulanco MC; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY, 10461, USA., Madsen AT; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY, 10461, USA.; Department of Urology, Albert Einstein College of Medicine, New York, NY, 10461, USA., Tanwar A; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY, 10461, USA.; Department of Oncology, Albert Einstein College of Medicine, New York, NY, 10461, USA., Corrigan DT; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY, 10461, USA., Zang X; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY, 10461, USA. xingxing.zang@einsteinmed.edu.; Department of Urology, Albert Einstein College of Medicine, New York, NY, 10461, USA. xingxing.zang@einsteinmed.edu.; Department of Oncology, Albert Einstein College of Medicine, New York, NY, 10461, USA. xingxing.zang@einsteinmed.edu.; Department of Medicine, Albert Einstein College of Medicine, New York, NY, 10461, USA. xingxing.zang@einsteinmed.edu.
Jazyk: angličtina
Zdroj: Cellular & molecular immunology [Cell Mol Immunol] 2023 Jul; Vol. 20 (7), pp. 694-713. Date of Electronic Publication: 2023 Apr 17.
DOI: 10.1038/s41423-023-01019-8
Abstrakt: The B7/CD28 families of immune checkpoints play vital roles in negatively or positively regulating immune cells in homeostasis and various diseases. Recent basic and clinical studies have revealed novel biology of the B7/CD28 families and new therapeutics for cancer therapy. In this review, we discuss the newly discovered KIR3DL3/TMIGD2/HHLA2 pathways, PD-1/PD-L1 and B7-H3 as metabolic regulators, the glycobiology of PD-1/PD-L1, B7x (B7-H4) and B7-H3, and the recently characterized PD-L1/B7-1 cis-interaction. We also cover the tumor-intrinsic and -extrinsic resistance mechanisms to current anti-PD-1/PD-L1 and anti-CTLA-4 immunotherapies in clinical settings. Finally, we review new immunotherapies targeting B7-H3, B7x, PD-1/PD-L1, and CTLA-4 in current clinical trials.
(© 2023. The Author(s), under exclusive licence to CSI and USTC.)
Databáze: MEDLINE
Externí odkaz: